No revenue reported as Dicot Pharma advances LIB-01, with phase 2a trial set for Q4 2024 and strong cash position after an oversubscribed rights issue. Nasdaq First North listing approved, and new R&D initiatives in metabolic diseases underway.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.